Center, Brian <br/><br/>
A phase I study of gefitinib with concurrent dose-escalated weekly docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel and maintenance gefitinib for patients with stage III non-small cell lung cancer.  [electronic resource] 

 -  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer  Jan 2010 
 - 69-74 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1556-1380 
<br/><br/><label>Standard No.: </label>10.1097/JTO.0b013e3181c59a0e  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Combined Modality Therapy<br/>Docetaxel<br/>Female<br/>Follow-Up Studies<br/>Gefitinib<br/>Humans<br/>Imaging, Three-Dimensional<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Neoplasm Staging<br/>Prognosis<br/>Quinazolines--administration & dosage<br/>Radiotherapy Dosage<br/>Radiotherapy, Conformal<br/>Survival Rate<br/>Taxoids--administration & dosage